Tisdag 14 Oktober | 14:32:57 Europe / Stockholm

Svenska | English

Hutchmed (China)

Kalender

	Est. tid*
2025-05-13	-	Årsstämma
2025-03-31	-	Extra Bolagsstämma
2024-08-01	-	Kvartalsrapport 2024-Q2
2019-05-30	-	Split HCM 1:10

Beskrivning

Land	Caymanöarna
Lista	52
Sektor	Hälsovård
Industri	Vård & Omsorg

Filter

År

Typ

Språk

Rensa

2025-10-14 10:30:00 HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

2025-10-13 06:00:00 HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress 232,00 GBP | -1,69% | 0,02 MGBP

2025-10-02 02:00:00 HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025 236,00 GBP | +2,16% | 0,01 MGBP

2025-09-12 02:00:00 Save the Date: HUTCHMED to Present R&D Updates on October 31, 2025 260,00 GBP | +8,79% | 0,35 MGBP

2025-09-05 02:00:00 HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025 233,50 GBP | +8,60% | 0,35 MGBP

2025-08-25 02:20:00 HUTCHMED Announces Appointment of Acting Chief Executive Officer

2025-08-20 02:00:00 HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China 236,50 GBP | -1,87% | 0,01 MGBP

2025-07-03 10:30:00 HUTCHMED to Announce 2025 Half-Year Financial Results 230,00 GBP | +4,07% | 0,10 MGBP

2025-06-30 10:30:00 HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy 227,00 GBP | +3,65% | 0,06 MGBP

2025-06-05 01:45:00 HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma 224,00 GBP | +3,23% | 0,22 MGBP

2025-06-02 02:00:00 HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting 201,00 GBP | -2,90% | 0,05 MGBP

2025-05-23 02:00:00 HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting 208,00 GBP | -0,48% | 0,02 MGBP

2025-04-24 02:00:00 HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025 237,00 GBP | +2,16% | 0,01 MGBP

2025-04-22 02:00:00 HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China 235,00 GBP | +10,85% | 0,13 MGBP

2025-03-21 11:00:00 HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma 227,00 GBP | -9,20% | 0,36 MGBP

2025-03-20 10:30:00 Intended Retirement of Independent Non-executive Directors and changes of composition of board committees 250,00 GBP | +2,04% | 0,07 MGBP

2025-03-20 01:00:00 HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025 250,00 GBP | +2,04% | 0,07 MGBP

2025-03-19 12:00:00 HUTCHMED Reports 2024 Full Year Results and Provides Business Updates 245,00 GBP | +6,52% | 0,10 MGBP

2025-03-19 01:00:00 HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China 245,00 GBP | +6,52% | 0,10 MGBP

2025-03-06 11:00:00 HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China 248,00 GBP | -4,25% | 0,05 MGBP

2025-03-05 11:00:00 HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee 259,00 GBP | +3,19% | 0,03 MGBP

2025-02-19 09:30:00 HUTCHMED to Announce 2024 Final Results 232,00 GBP | +6,42% | 0,23 MGBP

2025-01-14 05:00:00 HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC 252,00 GBP | +4,13% | 0,07 MGBP

2025-01-02 01:00:00 HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy 247,00 GBP | +5,11% | 0,11 MGBP

2025-01-01 11:46:43 HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture

2024-12-13 01:00:00 HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib) 247,00 GBP | -1,59% | 0,20 MGBP

2024-12-12 05:00:00 HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy 251,00 GBP | -3,46% | 0,26 MGBP

2024-12-03 11:00:00 HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer 279,00 GBP | -0,36% | 0,12 MGBP

2024-11-28 11:30:00 HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms 277,00 GBP | -4,48% | 0,06 MGBP

2024-11-22 05:30:00 HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan 278,00 GBP | -1,07% | 0,07 MGBP

2024-11-20 10:30:00 HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee 284,00 GBP | +9,23% | 0,33 MGBP

2024-11-06 05:00:00 HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress 284,00 GBP | -0,70% | 0,39 MGBP

2024-10-31 09:30:00 HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda 286,00 GBP | -2,05% | 0,25 MGBP

2024-10-16 06:30:00 HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial 303,00 GBP | +6,69% | 0,65 MGBP

2024-09-24 09:00:00 HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda 258,00 GBP | +1,98% | 0,25 MGBP

2024-09-09 02:00:00 HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer 261,00 GBP | -0,38% | 0,02 MGBP

2024-08-30 06:30:00 HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China 262,00 GBP | -2,96% | 0,27 MGBP

2024-08-21 10:30:00 HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia 273,00 GBP | -1,44% | 0,30 MGBP

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Hutchmed (China)

Kalender

Beskrivning

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden